1 November 2018 in Journal of Biological Chemistry
Asthma is thought to be caused by malfunction of type 2 T helper cell (Th2)-mediated immunity, causing excessive inflammation, mucus overproduction, and apoptosis of airway epithelial cells. Heme oxygenase-1 (HO-1) functions in heme catabolism and is both cytoprotective and anti-inflammatory. We hypothesized that this dual function may be related to asthma’s etiology. Using primary airway epithelial cells (pAECs) and an asthma mouse model, we demonstrate that severe lung inflammation is associated with rapid pAEC apoptosis. Surprisingly, NOD-like receptor protein 3 (NLRP3) inhibition, retinoid X receptor (RXR) deficiency, and HO-1 induction were associated with abrogated apoptosis. MCC950, a selective small-molecule inhibitor of canonical and noncanonical NLRP3 activation, reduced RXR expression, leading to decreased pAEC apoptosis that was reversed by the RXR agonist adapalene. Of note, HO-1 induction in a mouse model of ovalbumin-induced eosinophilic asthma suppressed Th2 responses and reduced apoptosis of pulmonary pAECs. In vitro, HO-1 induction desensitized cultured pAECs to ovalbumin-induced apoptosis, confirming the in vivo observations. Critically, the HO-1 products carbon monoxide and bilirubin suppressed the NLRP3–RXR axis in pAECs. Furthermore, HO-1 impaired production of NLRP3-RXR–induced cytokines (interleukin [IL]-25, IL-33, thymic stromal lymphopoietin [TSLP] and granulocyte-macrophage colony-stimulating factor [GM-SCF]) in pAECs and lungs. Finally, we demonstrate that HO-1 binds to the NACHT domain of NLRP3 and the RXRα and RXRβ subunits and that this binding is not reversed by Sn-protoporphyrin. Our findings indicate that HO-1 and its products are essential for pAEC survival to maintain airway epithelium homeostasis during NLRP3-RXR–mediated apoptosis and inflammation.
27 November 2021 in Clinical and Experimental Immunology
NLRP3 inflammasome hyperactivation contributes to neuroinflammation in autoimmune disorders, but the underlying regulatory mechanism remains to be elucidated. We demonstrate that compared with wild-type (WT) mice, mice lacking thymic stromal lymphopoietin (TSLP) receptor (TSLPR) (Tslpr−/− mice) exhibit a significantly decreased experimental autoimmune encephalomyelitis (EAE) score, reduced CD4+ T cell infiltration, and restored myelin basic protein (MBP) expression in the brain after EAE induction by myelin oligodendrocyte glycoprotein35–55 (MOG35–55). TSLPR signals through Janus kinase (JAK)2, but not JAK1 or JAK3, to induce NLRP3 expression, and Tslpr−/− mice with EAE show decreased JAK2 phosphorylation and NLRP3 expression in the brain. JAK2 inhibition by ruxolitinib mimicked loss of TSLPR function in vivo and further decreased TSLP expression in the EAE mouse brain. The NLRP3 inhibitor MCC950 decreased CD4+ T cell infiltration, restored MBP expression, and decreased IL-1β and TSLP levels, verifying the pro-inflammatory role of NLRP3. In vitro experiments using BV-2 murine microglia revealed that TSLP directly induced NLRP3 expression, phosphorylation of JAK2 but not JAK1orJAK3, and IL-1β release, which were markedly inhibited by ruxolitinib. Furthermore, EAE induction led to an increase in the Th17 cell number, a decrease in the regulatory T (Treg) cell number in the blood, and an increase in the expression of the cytokine IL-17A in the WT mouse brain, which was drastically reversed in Tslpr−/− mice. In addition, ruxolitinib suppressed the increase in IL-17A expression in the EAE mouse brain. These findings identify TSLP as a prospective target for treating JAK2-NLRP3 axis-associated autoimmune inflammatory disorders.
16 April 2020 in Pediatric Pulmonology
8 February 2024 in The FASEB Journal
1 May 2023 in Genes & Diseases
12 May 2022 in Research Square
Background: Anti-TNF-α antibody has been an efficient therapy for managing ulcerative colitis (UC). However, IgA vasculitis may be a rare complication that occurs during inflammatory bowel disease (IBD) or after TNF blocker treatment.Case presentation: We report a 14-year-old female patient with a history of purpuric skin lesions and UC. Two months prior to the current admission, she developed canker sores with fever, which was alleviated after the application of clindamycin hydrochloride. One month prior to the current admission, she was diagnosed with UC because of her abdominal pain and severe bloody diarrhoea. Ten days before admission, she developed a bilateral lower extremity purpuric rash. After admission, her abdominal symptoms mildly improved with glucocorticoids and infliximab. However, soon after, she developed two episodes of severe haematochezia and markedly aggravated purpura on the extensor side of both lower extremities. Following colonoscopy examination and intestinal IgA staining, she was diagnosed with IgA vasculitis, which induced severe haematochezia. We decided to continue the original treatment. After the fifth dose of infliximab, the gastrointestinal symptoms disappeared, and the purpuric rash resolved after 1 month.Discussion and conclusion: IgA vasculitis is a rare adverse effect of extraintestinal manifestations of UC, appearing at any age. IgA vasculitis is triggered by infections, specific drugs (infliximab, adalimumab, etanercept) and malignancy. The abdominal and intestinal manifestations of UC and IgA vasculitis may overlap, making it difficult to diagnose IgA vasculitis. Therefore, colonoscopy and intestinal biopsy with IgA staining are useful to detect intestinal involvement of IgA vasculitis.